Metrics to compare | SHRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSHRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −0.8x | −0.4x | |
PEG Ratio | −0.08 | −0.62 | 0.00 | |
Price/Book | −120.1x | 4.9x | 2.6x | |
Price / LTM Sales | - | 11.2x | 3.0x | |
Upside (Analyst Target) | - | 197.6% | 55.8% | |
Fair Value Upside | Unlock | 33.3% | 8.3% | Unlock |
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.